<DOC>
	<DOCNO>NCT01496547</DOCNO>
	<brief_summary>Patients refractory relapse leukemia poor outcome even allogeneic stem cell transplantation . In previous retrospective study , overall survival 14.6+/-8.8 % 90 % patient eventually relapse marrow ablative conditioning mostly standard iv-Bu-Cy Cy-TBI . The accumulated TRM 29.5+/-11.5 % . Thus data suggest conventional transplantation approach may able overcome refractory disease . A new strategy combine low dose regimen follow intensive chemotherapy tumor reduction seem effect relapse . high-risk refractory AML ALL . In study , focus new treatment strategy particular refractory AML patient .</brief_summary>
	<brief_title>Sequential Intensive Chemotherapy Followed RIC Refractory Relapse AML</brief_title>
	<detailed_description>This single arm phase II trial test efficacy feasibility new sequential intensive chemo transplantation approach refractory leukemia . Patients refractory acute myeloid lymphoblastic leukemia enrol trial . Patients receive intensive chemotherapy include Fludarabine , cytarabine idarubicin ( FLAG-IDA ) . Seven day chemotherapy , sequential transplantation condition regimen fludarabine busulfan give .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>adult patient refractory relapse acute myeloid leukemia remission 2 cycle induction chemotherapy early relapse ( 1st remission less 6 month ) remission 1 cycle reinduction chemotherapy multiple relapse age 1660 year inform consent contraindication allogeneic transplantation : active infection , allergy FLu/Bu/CTX , liver renal function damage HLA match relate ( 6/6 ) unrelated donor ( least 8/10 ) age le 18 year 61 year liver function/renal function damage ( 2 X upper normal range ) mental disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>feasibility , effective safety</keyword>
	<keyword>intensive chemotherapy</keyword>
	<keyword>RIC regimen</keyword>
	<keyword>refractory relapse leukemia</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
</DOC>